A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 12, 2023

Primary Completion Date

August 26, 2024

Study Completion Date

August 26, 2024

Conditions
Neovascular Age-related Macular Degeneration (NVAMD)Diabetic Macular Edema (DME)
Interventions
DRUG

EYE103

EYE103 is a humanized antibody formulated for IVT administration

Trial Locations (32)

1023

Caba, Argentina, Caba

21740

Hagerstown, MD, Hagerstown

29169

West Columbia, SC, West Columbia

33064

Pompano Beach, Pompano Beach

37203

Nashville, TN, Nashville

37922

Knoxville, TN, Knoxville

38138

Germantown, TN, Germantown

60439

Lemont, NV, Lemont

75075

Plano, TX, Plano

75231

Dallas, TX, Dallas

77384

The Woodlands, TX, The Woodlands

77401

Bellaire, TX, Bellaire

77494

Katy, TX, Katy

78240

San Antonio, TX, San Antonio

78503

McAllen, TX, McAllen

78681

Round Rock, TX, Round Rock

78705

Austin, TX, Austin

79109

Amarillo, TX, Amarillo

79606

Abilene, TX, Abilene

80288

Lakewood, CO, Lakewood

80909

Colorado Springs, Colorado, Colorado Springs

85032

Phoenix, AZ, Phoenix

89502

Reno, NV, Reno

93309

Bakersfield, CA, Bakersfield

94040

Mountain View, CA, Mountain View

95356

Modesto, CA, Modesto

95825

Sacramento, CA, Sacramento

95841

Sacramento, CA, Sacramento

C1121ABB

Ciudad Autonoma Buenos Aires, Ciudad Autonoma de Buenos Aires

00612

Arecibo, PR, Arecibo

NW10 7NS

London, England, London

W1G7LB

London, UK, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

EyeBiotech Ltd.

INDUSTRY

NCT05919693 - A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) | Biotech Hunter | Biotech Hunter